Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01206335
Other study ID # OHR-201
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received September 20, 2010
Last updated November 26, 2012
Start date September 2010
Est. completion date February 2013

Study information

Verified date November 2012
Source Ohr Pharmaceutical Inc.
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a previous study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain, improved mood; and decreased fatigue.


Description:

Advanced cancers are usually debilitating. There are few treatments available for symptoms of advanced cancers like loss of appetite, decreased strength, fatigue, and change in mood. This Phase II, open label study with OHR/AVR118 will enable the Sponsor to gather data on safety and efficacy of OHR/AVR118 in the patient population with anorexia-cachexia. Patients aged 18-85 with advanced cancers (excluding central nervous system [CNS] cancers) who may or may not be receiving chemotherapy, may be eligible to participate. The study drug, 4.0 mL, will be given subcutaneously each day for 28 days. Patients who respond to the trial period dosing will be eligible to continue on OHR/AVR118 if they and their physicians believe it would be beneficial, and if no safety concerns are raised.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date February 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Histologically confirmed solid tumor cancer, leukemia, lymphoma, or multiple myeloma.

- Concurrent anti-cancer treatment, such as chemotherapy or radiation therapy is permitted except for neo-adjuvant or adjuvant programs.

- Between the ages of 18-85.

- Symptoms of recurrent or metastatic cancer in which anorexia is a predominant symptom, not necessarily associated with cachexia, and are not attributed to anemia, concomitant illnesses, or obstruction or loss of organ function.

- Karnofsky performance status of 40%

- Palliative Prognostic Score (PaP) of less than 6

- Patient is expected to be able to remain on a study protocol for two months.

- Pretreatment laboratory data within 7 days of enrollment:

- Hemoglobin >8.5 g/dL , or on stable doses (hematocrit stable within 1 gram and dose stable for one month) of erythropoietin or similar medication.

- Absolute neutrophil count (ANC) 1,500/mm3.

- Platelets 50,000/mm3.

- Total bilirubin 2.0

- ALT and AST 2.5 times the ULN, or, if the patient has liver metastases, 5 times the ULN.

- Creatinine 1.5 mg/dL.

- Normal TSH

- Testosterone levels determined.

- Voluntary written informed consent before performance of any study-related procedure that is not part of normal medical care.

- Ability to self-administer subcutaneous medication if an assistant or nurse is not available, and to keep a compliance journal documenting injections at home.

- If on an antidepressant, the dose must have been stabilized for at least 30 days.

- Female patient is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of the study.

- Male patient agrees to use an acceptable barrier method for contraception during the study

Exclusion Criteria:

- Patient has uncontrolled brain metastases or central nervous system disease.

- Patient has mechanical, non-reversible reason for not being able to eat, or have a potential for developing malignant bowel obstruction during the course of the induction phase of treatment, or patients requiring a PEG for obstruction.

- Patient has had any major surgery within four weeks of enrollment.

- Patient has an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

- In the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.

- Female patient is pregnant or breast-feeding.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
OHR/AVR118
OHR/AVR118 given subcutaneously at 4mL per day

Locations

Country Name City State
Canada Ottawa Hospital Cancer Centre Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ohr Pharmaceutical Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alleviation of multiple cachexia symptoms Functional Status/Quality of Life as assessed by Simmonds Functional Assessment (SFA); Appetite and early satiety as assesed by patetient-generated subjective global assessment (PG-SGA), Edmonton Symptom assessment Scale (ESAS) and dyspepsia symptom severity index (DSSI); weight gain; increase in lean body mass. Four weeks No
Secondary Impact on inflammatory markers and hormonal milieu Measurement of effects on Testosterone, TSH and C-Reactive protein 4 weeks No
See also
  Status Clinical Trial Phase
Withdrawn NCT01501396 - Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite Phase 2
Withdrawn NCT02793102 - Sensory Workshops and Anorexia Nervosa N/A
Completed NCT02524301 - Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study N/A
Active, not recruiting NCT00488072 - Effects of Mirtazapine on Appetite in Advanced Cancer Patients Phase 2
Withdrawn NCT05039385 - Exercise Program in Patients With Anorexia Nervosa (ESATRAL) N/A
Completed NCT03097874 - Adaptive Treatment for Adolescent Anorexia Nervosa N/A
Completed NCT00031785 - Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer Phase 3
Terminated NCT00535015 - Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer Phase 2
Terminated NCT00558558 - Haelan and Nutrition in Cancer Patients Phase 2
Completed NCT00040885 - Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05) Phase 3
Completed NCT00006799 - Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Phase 3
Active, not recruiting NCT03637816 - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Phase 2/Phase 3
Completed NCT04007900 - Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa N/A
Completed NCT00735540 - Clinical Diagnosis of Teenagers Admitted to Pediatric Departments N/A
Completed NCT00046904 - Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer Phase 3
Completed NCT04803305 - Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia Phase 1
Completed NCT05708404 - Outpatient Treatment of Severe and Enduring Anorexia Nervosa
Completed NCT03283488 - Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Phase 2
Recruiting NCT05503147 - Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan) Phase 1
Terminated NCT01200602 - Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy Phase 2